

Five Giralda Farms
Madison, NJ 07940

and (Andy) Iyer, Ph.D.
Patent Attorney
Law Department, Patent Section
845 602-2189 tel
iyera@wyeth.com

JC14 Rec'd PCT/PTO 13 MAY 2002

S.N.09/674368

PCT
#6

Wyeth

May 2, 2002

Mr. Robert Sparr, Esq.
U.S. Patent and Trademark Office
Washington, D.C. 20231



RECEIVED

25 JUN 2002

Legal Coun
International Division

Re: U.S. Application No. ACY-33377-00
Serial No. 09/674368
Assignee: American Cyanamid Company
Inventors: Metcalf et al.
Title: Vaccines Containing Recombinant Pilin Against Neisseria Gonorrhoeae

Dear Mr. Sparr:

I am writing this letter, pursuant to our telephone conversation of April 24, 2002, to request you to make a determination as to whether, based on the facts set out below, the Patent Office (the "Office") would be willing to withdraw the holding of abandonment in the above-identified application and provide the Applicants with an extension of time to respond to the "Notification of Defective Response."

STATEMENT OF MATERIAL FACTS AND REASONS FOR GRANTING RELIEF

The above-identified application (U.S. serial No. 09/674368) was filed as a "National Stage" application under 35 U.S.C. §371 on October 27, 2000, from a PCT application, International Application Number PCT/US99/09486, filed on April 29, 1999, and claims priority from U.S. Provisional Application No. 60/083,405 filed April 29, 1998.

The application as filed contained a sequence listing both in a computer readable form and as a paper copy, which was generated using PatentIn Version 2.0.

BEST AVAILABLE COPY

Wyeth Pharmaceuticals
Wyeth Consumer Healthcare
Fort Dodge Animal Health

On June 11, 2001, the Office mailed a "Notification to Comply with Requirements for Patent Application Containing Nucleotide Sequences and/or Amino Acid Disclosures" (the "Notification"), wherein the Office stated that the "computer readable form that had been filed with this application has been found to be damaged and/or unreadable" and requested the Applicants to submit a substitute computer readable sequence listing as required under 37 C.F.R. §§ 1.821 – 1.825. Specifically, in the Raw Sequence Listing Error Report (the "Report") mailed with the Notification the following errors were identified:

- (1) The number/text at the end of each line wrapped down to the next line; and
- (2) The file was not saved in ASC II (DOS) text as required by the sequence rules. (see Exhibit 1).

The report further cautioned the Applicants not to use the "copy to disk" function of the PatentIn Version 2.0 as a "bug" in the software would cause a corrupted file resulting in missing mandatory numeric identifiers and responses.

On December 12, 2001, the Applicants filed a response to the "Notification" with a petition for extension of time and fees. Along with the response, the Applicants submitted a substitute computer readable form and a paper copy of the sequence listing wherein the Applicants corrected the errors that were identified in the Report, together with a statement as required under 37 C.F.R. §§ 1.825. In generating the computer readable form of the sequence listing, wherein the errors identified in the Report were corrected, the Applicants used PatentIn Version 3.0 and the "Sequence Checker" function of Version 3.0.

On March 18, 2002, the Office mailed a "Notification of Defective Response" and set a "time limit of one month from the date of this Notification or the Notice of Missing Requirements, whichever is longer." The only error identified in the Raw Sequence Listing Error Summary Report that was sent with the Notification of Defective Response was an error caused by a "bug" in PatentIn Version 2.0, which caused sections <220> through <223> to be missing from amino acid sequences 2 and 4. (see Exhibit 2). The Report in paragraph 6

further stated that, “[n]ormally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence,” and that the only way to rectify this error is to “manually copy the relevant <220> <223> section to the subsequent amino acid sequence.”

The Applicants respectfully submit that the Applicants followed the suggestions of the Office in generating a substitute computer readable form of the sequence listing in responding to the Notification of July 11, 2001. The Applicants submit that due to software incompatibility between PatentIn Version 2.0 and the Version 3.0, the software failed to automatically generate sections <220> through <223> in the amino acid sequences 2 and 4. Furthermore, since the March 18, 2002 suggestion to manually copy the relevant sections <220> through <223> from the nucleic acid sequence 1 and 3 into the amino acid sequences 2 and 4 was not made in the “Raw Sequence Listing Error Report” mailed with the “Notification” of July 11, 2001, the Applicants were unaware that the missing mandatory sections needed to be corrected.


In view of the above, the Applicants respectfully request that the Office withdraw the holding of abandonment. The Applicants further request that the Applicants be granted an extension of time to file a response to the “Notification of Defective Response” together with a substitute computer readable form of the sequence listing.

CONCLUSION

In view of the material facts set forth above, the Applicants respectfully request that the holding of abandonment be withdrawn, and the Applicants be granted relief to submit a substitute corrected computer readable form of the sequence listing.

Should you need to contact me or need any additional information, please do not hesitate to call me at #(845) 602-2189.

Sincerely yours,


Anand (Andy) P. Iyer, Ph.D.




Alan M. Gordon
Reg. No. 30,637
Attorney for Applicants

AIP/awp

Wyeth

S.N.09/674368

EXHIBIT A



29 APR 99

DATE MAILED:

11 JUN 2001

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ☐ The application fails to comply with the requirements of 37 CFR 1.821-1.825.
- ☐ This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- ☐ A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
- ☐ A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☒ The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ Other: _____

APPLICANT MUST PROVIDE:


- ☒ An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- ☐ An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

**FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
CALL:**

(703) 308-4216, for Rules interpretation,
(703) 308-4212, for CRF submission help,
(703) 287-0200, for PatentIn software help.

Deborah D. Williams 

Telephone: 703-305-3744



DATE MA 1 JUN 2001

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as ☐ a Designated Office (37 CFR 1.494) ☒ an Elected Office (37 CFR 1.495):

- | | |
|--|--|
| <input checked="" type="checkbox"/> U.S. Basic National Fee. | <input type="checkbox"/> Indication of Small Entity Status. |
| <input checked="" type="checkbox"/> Copy of the international application. | <input checked="" type="checkbox"/> Translation of the international application into English. |
| <input checked="" type="checkbox"/> Oath or Declaration of inventors(s). | <input type="checkbox"/> Translation of Article 19 amendments into English. |
| <input type="checkbox"/> Copy of Article 19 amendments. | <input type="checkbox"/> Other: |
| <input type="checkbox"/> Priority Document. | |
| <input checked="" type="checkbox"/> The International Preliminary Examination Report in English and its Annexes, if any. | |
| <input type="checkbox"/> Translation of Annexes to the International Preliminary Examination Report into English. | |

2. ☐ Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items and/or the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be filed prior to 20 or 30 months from the priority date to avoid abandonment.

- ☐ U.S. Basic National Fee. ☐ Copy of the international application.

3. The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- ☐ a. Translation of the application into English. A processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date.
- ☐ The current translation is defective for the reasons indicated on the attached Notice of Defective Translation.
- ☐ b. Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)).
- ☐ c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying the application (preferably by the International application number and international filing date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date.
- ☐ The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.
- ☐ d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)).

4. Additional claim fees of \$_____ as a ☐ large entity ☐ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.

5. ☒ Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.

ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

6. If box 3a or 3c is checked, a translation of the Annexes **MUST** be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.

7. ☐ The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

A copy of this notice MUST be returned with this response.

- Enclosed: ☐ PCT/DO/EO/917 ☐ Notice of Defective Translation
☐ PTO-875 ☒ PCT/DO/EO/920

Deborah D. Williams

I.A. FILING DATE

PRIORITY DATE

29 APR 99

DATE MAILED:

11 JUN 2001

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as ☐ a Designated Office (37 CFR 1.494) ☒ an Elected Office (37 CFR 1.495):
- ☒ U.S. Basic National Fee. ☐ Indication of Small Entry Status.
 - ☒ Copy of the international application. ☒ Translation of the international application into English.
 - ☒ Oath or Declaration of inventors(s). ☐ Translation of Article 19 amendments into English.
 - ☐ Copy of Article 19 amendments. ☐ Other:
 - ☐ Priority Document.
 - ☒ The International Preliminary Examination Report in English and its Annexes, if any.
 - ☐ Translation of Annexes to the International Preliminary Examination Report into English.
2. ☐ Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items and/or the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be filed prior to 20 or 30 months from the priority date to avoid abandonment.
- ☐ U.S. Basic National Fee.
 - ☐ Copy of the international application.
3. The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:
- ☐ a. Translation of the application into English. A processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date.
 - ☐ The current translation is defective for the reasons indicated on the attached Notice of Defective Translation.
 - ☐ b. Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)).
 - ☐ c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying the application (preferably by the international application number and international filing date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date.
 - ☐ The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.
 - ☐ d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)).
4. Additional claim fees of \$_____ as a ☐ large entity ☐ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.
5. ☒ Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.

ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

6. If box 3a or 3c is checked, a translation of the Annexes **MUST** be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.
7. ☐ The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

A copy of this notice MUST be returned with this response.

- Enclosed: ☐ PCT/DO/EO/917 ☐ Notice of Defective Translation
☐ PTO-875 ☒ PCT/DO/EO/920

Deborah D. Williams


Telephone: 703-305-3744

FORM PCT/DO/EO/905 (March 2001)

RECEIVED

JUN 13 2001

ANNEITE CROMER



RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/674,368

Source: PCT/09

Date Processed by STIC: 3/07/2001

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER
VERSION 3.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND
TRADEMARK OFFICE WEBSITE. SEE BELOW.

Checker Version 3.0

The Checker Version 3.0 application is a state-of-the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 - 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address:



Raw Sequence Listing Error Summary

ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER: 09/674,368

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 ☒ 1 Wrapped Nucleics The number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 2 ☐ 2 Wrapped Aminos The amino acid number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 3 ☐ 3 Incorrect Line Length The rules require that a line not exceed 72 characters in length. This includes spaces.
- 4 ☐ 4 Misaligned Amino Acid Numbering The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.
- 5 ☒ 5 Non-ASCII This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
- 6 ☐ 6 Variable Length Sequence(s) contain n's or Xaa's which represented more than one residue.
As per the rules, each n or Xaa can only represent a single residue.
Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.
- 7 ☐ 7 PatentIn ver. 2.0 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 8 ☐ 8 Skipped Sequences (OLD RULES) Sequence(s) missing. If intentional, please use the following format for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X:
(i) SEQUENCE CHARACTERISTICS: (Do not insert any headings under "SEQUENCE CHARACTERISTICS")
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:X:
This sequence is intentionally skipped

Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
- 9 ☐ 9 Skipped Sequences (NEW RULES) Sequence(s) missing. If intentional, please use the following format for each skipped sequence.
<210> sequence id number
<400> sequence id number
000
- 10 ☐ 10 Use of n's or Xaa's (NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.
Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 11 ☐ 11 Use of <213> Organism (NEW RULES) Sequence(s) are missing this mandatory field or its response.
- 12 ☐ 12 Use of <220> Feature (NEW RULES) Sequence(s) are missing the <220> Feature and associated headings.
Use of <220> to <223> is MANDATORY if <213> ORGANISM is "Artificial" or "Unknown"
Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rule)
- 13 ☒ 13 PatentIn ver. 2.0 "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).
Instead, please use "File Manager" or any other means to copy file to floppy disk.



Page 1

PC:

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/674,368

DATE: 03/07/2001
TIME: 11:37:48

Input Set : A:\PTO.txt
Output Set: N:\CRF3\03072001\I674368.raw

Does Not Comply
Corrected Diskette Needed

OK 5 <110> APPLICANT: American Cyanamid Company
7 <120> TITLE OF INVENTION: Vaccines Containing Recombinant Pilin Against Neisseria
9 Gonorrhoeae or Neisseria Meningitidis
11 <130> FILE REFERENCE: 33377-00/PCT
13 <140> CURRENT APPLICATION NUMBER: US/09/674,368
14 <141> CURRENT FILING DATE: 2000-10-27
16 <160> NUMBER OF SEQ ID NOS: 24
18 <170> SOFTWARE: PatentIn Ver. 2.0

*see item 5 on Enol
Summary Sheet*

ERRORED SEQUENCES

299 <210> SEQ ID NO: 13
300 <211> LENGTH: 31
301 <212> TYPE: DNA
303 <213> ORGANISM: Neisseria Meningitidis Class I
305 <400> SEQUENCE: 13

E--> 306 ccggcgcgctc tctcacggcg aatggcccg c
307 31

move up - format enol

(see item 1 on

*Enol Summary
Sheet)*

396 <210> SEQ ID NO: 24
397 <211> LENGTH: 22
398 <212> TYPE: PRT
399 <213> ORGANISM: Neisseria gonorrhoeae
404 <400> SEQUENCE: 24
405 Glu Ala Ile Leu Leu Ala Glu Gly Gln Lys Ser Ala Val Thr Glu Tyr
406 1 5 10 15
408 Tyr Leu Asn His Gly Lys
410 20

E--> 441 1

E--> 443 8

445 ACY-33377-00

delete at end of file

see following pages for more errors

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/674,368

DATE: 03/07/2001

TIME: 11:37:50

Input Set : A:\PTO.txt

Output Set: N:\CRF3\03072001\I674368.raw

L:13 M:270 C: Current Application Number differs, Replaced Application Number
L:14 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:60 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:64 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:68 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:72 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:76 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:80 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:87 M:258 W: Mandatory Feature missing, <220> FEATURE:
L:87 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:
L:194 M:258 W: Mandatory Feature missing, <220> FEATURE:
L:194 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:
L:306 M:254 E: No. of Bases conflict, LENGTH:Input:0 Counted:31 SEQ:13
L:441 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:24
M:332 Repeated in SeqNo=24

4

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/09/674,368
 DATE: 03/14/2001
 TIME: 12:10:34

Input Set : A:\Pto.amc
 Output Set: N:\CRF3\03142001\I674368.raw

```

142 1 5 10 15
144 atc gcc atc gtc ggt atc ttg gca gcc gtc gcc ctg ccc gca tac caa 96
145 ile ala ile val gly ile leu ala ala val ala leu pro ala tyr gln
146 20 25 30
148 gac tac acc gcg cgc gcc caa atg tcc gaa gcc ctg act ttg gca gaa 144
149 asp tyr thr ala arg ala gln met ser glu ala leu thr leu ala glu
150 35 40 45
152 ggt caa aaa tcc gca gtg atc gag tat tat tcc gac aac ggc aca ttc 192
153 gly gln lys ser ala val ile glu tyr tyr ser asp asn gly thr phe
154 50 55 60
156 ccg aac agc aat act tcc gca ggt att gct gcc tct aac gag att aaa 240
157 pro asn ser asn thr ser ala gly ile ala ala ser asn glu ile lys
158 65 70 75 80
160 ggt aag tat gtg gca tgc gtt aag gtt gaa ggt aat gcc tct gtt gct 288
161 gly lys tyr val ala ser val lys val glu gly asn ala ser val ala
162 85 90 95
164 tct att acc gct acc atg aac tct agt aat gtg aat aag gac atc aaa 336
165 ser ile thr ala thr met asn ser ser asn val asn lys asp ile lys
166 100 105 110
169 ggt aaa acc ttg gta ctc gtc ggc aaa caa aac tcc ggt tgc gta aaa 384
170 gly lys thr leu val leu val gly lys gln asn ser gly ser val lys
171 115 120 125
173 tgg ttc tgc gga cag ccg gtt acg cgc gac aac gcc gac aac gac gac 432
174 trp phe cys gly gln pro val thr arg asp asn ala asp asn asp asp
175 130 135 140
177 gtc aaa gac gcc ggc aac aac ggc atc gaa acc aag cac ctg ccg tca 480
178 val lys asp ala gly asn asn gly ile glu thr lys his leu pro ser
179 145 150 155 160
181 acc tgc cgc gat acg tca tct gat gcc aaa 510
182 thr cys arg asp thr ser ser asp ala lys
183 165 170
186 <210> SEQ ID NO: 4
187 <211> LENGTH: 170
188 <212> TYPE: PRT
189 <213> ORGANISM: Artificial Sequence

```

W-->
 W-->

```

191 <220> FEATURE:
191 <223> OTHER INFORMATION:
191 <400> SEQUENCE: 4
192 Met Glu Ala Ile Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val
193 1 5 10 15
195 Ile Ala Ile Val Gly Ile Leu Ala Ala Val Ala Leu Pro Ala Tyr Gln
196 20 25 30
198 Asp Tyr Thr Ala Arg Ala Gln Met Ser Glu Ala Leu Thr Leu Ala Glu
199 35 40 45
201 Gly Gln Lys Ser Ala Val Ile Glu Tyr Tyr Ser Asp Asn Gly Thr Phe
202 50 55 60
204 Pro Asn Ser Asn Thr Ser Ala Gly Ile Ala Ala Ser Asn Glu Ile Lys
205 65 70 75 80
207 Gly Lys Tyr Val Ala Ser Val Lys Val Glu Gly Asn Ala Ser Val Ala

```

→ same env - see item 13
 on Env
 Summary Sheet

3

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/674,368 DATE: 03/14/2001
TIME: 12:10:34

Input Set : A:\Pto.amc
Output Set: N:\CRF3\03142001\I674368.raw

W--> 71 gcc aag acc gcc gac aac atc aac acc aag cac ctg ccg tca acc tgc 480
72 Ala Lys Thr Ala Asp Asn Ile Asn Thr Lys His Leu Pro Ser Thr Cys
W--> 73 145 150 155 160
75 cgc gac gca agt gat gcc agc taa 504
76 Arg Asp Ala Ser Asp Ala Ser
W--> 77 165
79 <210> SEQ ID NO: 2
80 <211> LENGTH: 167
81 <212> TYPE: PRT
82 <213> ORGANISM: Artificial Sequence
W--> 84 <220> FEATURE:
W--> 84 <223> OTHER INFORMATION: *see item 13 on*
84 <400> SEQUENCE: 2 *Error*
85 Met Asp Thr Leu Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val
86 1 5 10 15
88 Ile Ala Ile Val Gly Ile Leu Ala Ala Val Ala Leu Pro Ala Tyr Gln
89 20 25 30
92 Asp Tyr Thr Ala Arg Ala Gln Val Ser Glu Ala Ile Leu Leu Ala Glu
93 35 40 45
96 Gly Gln Lys Ser Ala Val Thr Glu Tyr Tyr Leu Asn His Gly Glu Trp
97 50 55 60
100 Pro Gly Asn Asn Thr Ser Ala Gly Val Ala Ser Ser Ser Thr Ile Lys
101 65 70 75 80
104 Gly Lys Tyr Val Lys Glu Val Thr Val Ala Asn Gly Val Ile Thr Ala
105 85 90 95
108 Thr Met Leu Ser Ser Gly Val Asn Lys Glu Ile Gln Gly Lys Lys Leu
109 100 105 110
112 Ser Leu Trp Ala Lys Arg Gln Asp Gly Ser Val Lys Trp Phe Cys Gly
113 115 120 125
115 Gln Pro Val Thr Arg Thr Asp Ala Lys Ala Asp Thr Val Ala Ala Ala
116 130 135 140
118 Ala Lys Thr Ala Asp Asn Ile Asn Thr Lys His Leu Pro Ser Thr Cys
119 145 150 155 160
121 Arg Asp Ala Ser Asp Ala Ser
122 165
125 <210> SEQ ID NO: 3
126 <211> LENGTH: 510
127 <212> TYPE: DNA
128 <213> ORGANISM: Artificial Sequence
130 <220> FEATURE:
131 <223> OTHER INFORMATION: Description of Artificial Sequence: Chimeric of
132 Neisseria Meningitidis Class II and Neisseria
133 Gonorrhoeae
135 <220> FEATURE:
136 <221> NAME/KEY: CDS
137 <222> LOCATION: (1)...(510)
139 <400> SEQUENCE: 3
140 atg gaa gca atc caa aaa ggt ttc acc ctg atc gag ctg atg atc gtc 48
141 Met Glu Ala Ile Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val

*Summary
Sheet*

Wyeth

S.N.09/674368

EXHIBIT B



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov


U.S. APPLICATION NUMBER NO. 09/674,368	FIRST NAMED APPLICANT Thomas N III Metcalf	ATTY. DOCKET NO. 33377-00
---	---	------------------------------

Alan M Gordon
Patent Law Department 2B
American Home Products Corporation
One Campus Drive
Parsippany, NJ 07054



INTERNATIONAL APPLICATION NO. PCT/US99/09486	
I.A. FILING DATE 04/29/1999	PRIORITY DATE

CONFIRMATION NO. 6981
371 FORMALITIES LETTER



OC000000007646414

Date Mailed: 03/18/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- **APPLICANT MUST PROVIDE:**
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."

• For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

DEBORAH D WILLIAMS


Telephone: (703) 305-3744

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/674,368	PCT/US99/09486	33377-00



RAW SEQUENCE LISTING ERROR REPORT



DL
SUBD
12-31-2001
Mail

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/674,368 A
Source: Pt 109
Date Processed by STIC: 2/6/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.
PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)
PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER** VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/efb/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name,
Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,
2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION	SERIAL NUMBER: 09/674,368A
TTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE		
1 _____ Wrapped Nucleics _____ Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."	
1 _____ Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.	
1 _____ Misaligned Amino _____ Numbering	The numbering under each 5 th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.	
1 _____ Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.	
1 _____ Variable Length	Sequence(s) _____ contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.	
1 _____ PatentIn 2.0 _____ "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) <u>2,4</u> . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.	
_____ Skipped Sequences (OLD RULES)	Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.	
_____ Skipped Sequences (NEW RULES)	Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000	
_____ Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa; and which residue n or Xaa represents.	
_____ Invalid <213> _____ Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence	
_____ Use of <220>	Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)	
_____ PatentIn 2.0 _____ "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.	
_____ Misuse of n	n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.	



PCT09

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/674,368A

DATE: 02/06/2002
TIME: 14:15:57

Input Set : A:\33377PCT.APP.txt
Output Set: N:\CRF3\02062002\I674368A.raw

pat-3
**Does Not Comply
Corrected Diskette Needed**

5 <110> APPLICANT: American Cyanamid Company
7 <120> TITLE OF INVENTION: Vaccines Containing Recombinant Pilin Against Neisseria
9 Gonorrhoeae or Neisseria Meningitidis
11 <130> FILE REFERENCE: 33377-00/PCT
13 <140> CURRENT APPLICATION NUMBER: US/09/674,368A
14 <141> CURRENT FILING DATE: 2001-12-11
16 <160> NUMBER OF SEQ ID NOS: 24
18 <170> SOFTWARE: PatentIn Ver. 2.0
20 <210> SEQ ID NO: 1
21 <211> LENGTH: 504
22 <212> TYPE: DNA
23 <213> ORGANISM: Artificial Sequence
25 <220> FEATURE:
26 <223> OTHER INFORMATION: Description of Artificial Sequence:Chimeric of
27 Neisseria Meningitidis Class I and Neisseria
28 Gonorrhoeae
30 <220> FEATURE:
31 <221> NAME/KEY: CDS
32 <222> LOCATION: (1)..(501)
34 <400> SEQUENCE: 1
36 atg gat acc ctt caa aaa ggc ttt acc ctt atc gag ctg atg att gtg 48
37 Met Asp Thr Leu Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val
38 1 5 10 15
40 atc gcc atc gtc ggc att ttg gcg gca gtc gcc ctt ccc gcc tac caa 96
41 Ile Ala Ile Val Gly Ile Leu Ala Ala Val Ala Leu Pro Ala Tyr Gln
42 20 25 30
44 gac tac acc gcc cgc gcg caa gtt tcc gaa gcc atc ctt ttg gcc gaa 144
45 Asp Tyr Thr Ala Arg Ala Gln Val Ser Glu Ala Ile Leu Leu Ala Glu
46 35 40 45
48 ggt caa aaa tca gcc gtt acc gag tat tac ctg aat cac ggc gaa tgg 192
49 Gly Gln Lys Ser Ala Val Thr Glu Tyr Tyr Leu Asn His Gly Glu Trp
50 50 55 60
52 ccc ggc aac aac act tct gcc ggc gtg gca tct tct tca aca atc aaa 240
53 Pro Gly Asn Asn Thr Ser Ala Gly Val Ala Ser Ser Ser Thr Ile Lys
54 65 70 75 80
58 ggc aaa tat gtt aag gaa gtt aca gtc gca aac ggc gtc att acc gcc 288
~~59 Gly Lys Tyr Val Lys Glu Val Thr Val Ala Asn Gly Val Ile Thr Ala~~
60 ~~85 90 95 95~~ *← for numbering*
62 aca atg ctt tca agc ggc gta aac aaa gaa atc caa ggc aaa aaa ctc 336
63 Thr Met Leu Ser Ser Gly Val Asn Lys Glu Ile Gln Gly Lys Lys Leu
64 100 105 110
66 tcc ctg tgg gcc aag cgt caa gac ggt tgc gta aaa tgg ttc tgc gga 384
67 Ser Leu Trp Ala Lys Arg Gln Asp Gly Ser Val Lys Trp Phe Cys Gly

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/674,368A

DATE: 02/06/2002

TIME: 14:15:57

Input Set : A:\33377PCT.APP.txt

Output Set: N:\CRF3\02062002\I674368A.raw

```

-> 68          115          120          125
70 cag ccg gtt acg cgc acc gac gcc aaa gcc gac acc gtc gcc gcc gcc 432
71 Gln Pro Val Thr Arg Thr Asp Ala Lys Ala Asp Thr Val Ala Ala Ala
-> 72          130          135          140
74 gcc aag acc gcc gac aac atc aac acc aag cac ctg ccg tca acc tgc 480
75 Ala Lys Thr Ala Asp Asn Ile Asn Thr Lys His Leu Pro Ser Thr Cys
-> 76 145          150          155          160
78 cgc gac gca agt gat gcc agc taa 504
79 Arg Asp Ala Ser Asp Ala Ser

```

```

-> 80          165
82 <210> SEQ ID NO: 2
83 <211> LENGTH: 167
84 <212> TYPE: PRT
85 <213> ORGANISM: Artificial Sequence
-> 87 <220> FEATURE:
-> 87 <223> OTHER INFORMATION:
87 <400> SEQUENCE: 2

```

see item 6 on Euro Summary Sheet

```

88 Met Asp Thr Leu Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val
89 1          5          10          15
91 Ile Ala Ile Val Gly Ile Leu Ala Ala Val Ala Leu Pro Ala Tyr Gln
92          20          25          30
95 Asp Tyr Thr Ala Arg Ala Gln Val Ser Glu Ala Ile Leu Leu Ala Glu
96          35          40          45
99 Gly Gln Lys Ser Ala Val Thr Glu Tyr Tyr Leu Asn His Gly Glu Trp
100          50          55          60
103 Pro Gly Asn Asn Thr Ser Ala Gly Val Ala Ser Ser Thr Ile Lys
104 65          70          75          80
107 Gly Lys Tyr Val Lys Glu Val Thr Val Ala Asn Gly Val Ile Thr Ala
108          85          90          95
111 Thr Met Leu Ser Ser Gly Val Asn Lys Glu Ile Gln Gly Lys Lys Leu
112          100          105          110
115 Ser Leu Trp Ala Lys Arg Gln Asp Gly Ser Val Lys Trp Phe Cys Gly
116          115          120          125
118 Gln Pro Val Thr Arg Thr Asp Ala Lys Ala Asp Thr Val Ala Ala Ala
119          130          135          140
121 Ala Lys Thr Ala Asp Asn Ile Asn Thr Lys His Leu Pro Ser Thr Cys
122 145          150          155          160
124 Arg Asp Ala Ser Asp Ala Ser
125          165

```

```

128 <210> SEQ ID NO: 3
129 <211> LENGTH: 510
130 <212> TYPE: DNA
131 <213> ORGANISM: Artificial Sequence
133 <220> FEATURE:
134 <223> OTHER INFORMATION: Description of Artificial Sequence:Chimeric of
135 Neisseria meningitidis Class II and Neisseria
136 Gonorrhoeae
138 <220> FEATURE:
139 <221> NAME/KEY: CDS

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/674,368A

DATE: 02/06/2002

TIME: 14:15:57

Input Set : A:\33377PCT.APP.txt

Output Set: N:\CRF3\02062002\I674368A.raw

140 <222> LOCATION: (1)..(510)

142 <400> SEQUENCE: 3

```

143 atg gaa gca atc caa aaa ggt ttc acc ctg atc gag ctg atg atc gtc      48
144 Met Glu Ala Ile Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val
145   1           5           10           15
147 atc gcc atc gtc ggt atc ttg gca gcc gtc gcc ctg ccc gca tac caa      96
148 Ile Ala Ile Val Gly Ile Leu Ala Ala Val Ala Leu Pro Ala Tyr Gln
149           20           25           30
151 gac tac acc gcg cgc gcc caa atg tcc gaa gcc ctg act ttg gca gaa      144
152 Asp Tyr Thr Ala Arg Ala Gln Met Ser Glu Ala Leu Thr Leu Ala Glu
153           35           40           45
155 ggt caa aaa tcc gca gtg atc gag tat tat tcc gac aac ggc aca ttc      192
156 Gly Gln Lys Ser Ala Val Ile Glu Tyr Tyr Ser Asp Asn Gly Thr Phe
157           50           55           60
159 ccg aac agc aat act tcc gca ggt att gct gcc tct aac gag att aaa      240
160 Pro Asn Ser Asn Thr Ser Ala Gly Ile Ala Ala Ser Asn Glu Ile Lys
161 65           70           75           80
163 ggt aag tat gtg gca tcg gtt aag gtt gaa ggt aat gcc tct gtt gct      288
164 Gly Lys Tyr Val Ala Ser Val Lys Val Glu Gly Asn Ala Ser Val Ala
165           85           90           95
167 tct att acc gct acc atg aac tct agt aat gtg aat aag gac atc aaa      336
168 Ser Ile Thr Ala Thr Met Asn Ser Ser Asn Val Asn Lys Asp Ile Lys
169           100          105          110
172 ggt aaa acc ttg gta ctc gtc ggc aaa caa aac tcc ggt tcg gta aaa      384
173 Gly Lys Thr Leu Val Leu Val Gly Lys Gln Asn Ser Gly Ser Val Lys
174           115          120          125
176 tgg ttc tgc gga cag ccg gtt acg cgc gac aac gcc gac aac gac gac      432
177 Trp Phe Cys Gly Gln Pro Val Thr Arg Asp Asn Ala Asp Asn Asp Asp
178           130          135          140
180 gtc aaa gac gcc ggc aac aac ggc atc gaa acc aag cac ctg ccg tca      480
181 Val Lys Asp Ala Gly Asn Asn Gly Ile Glu Thr Lys His Leu Pro Ser
182 145           150          155          160
184 acc tgc cgc gat acg tca tct gat gcc aaa      510
185 Thr Cys Arg Asp Thr Ser Ser Asp Ala Lys
186           165          170

```

189 <210> SEQ ID NO: 4

190 <211> LENGTH: 170

191 <212> TYPE: PRT

192 <213> ORGANISM: Artificial Sequence

194 <220> FEATURE:

194 <223> OTHER INFORMATION:

194 <400> SEQUENCE: 4

```

195 Met Glu Ala Ile Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val
196   1           5           10           15
198 Ile Ala Ile Val Gly Ile Leu Ala Ala Val Ala Leu Pro Ala Tyr Gln
199           20           25           30
201 Asp Tyr Thr Ala Arg Ala Gln Met Ser Glu Ala Leu Thr Leu Ala Glu
202           35           40           45
204 Gly Gln Lys Ser Ala Val Ile Glu Tyr Tyr Ser Asp Asn Gly Thr Phe

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/674,368A

DATE: 02/06/2002

TIME: 14:15:57

Input Set : A:\33377PCT.APP.txt

Output Set: N:\CRF3\02062002\I674368A.raw

```

205      50      55      60
207 Pro Asn Ser Asn Thr Ser Ala Gly Ile Ala Ala Ser Asn Glu Ile Lys
208 65      70      75      80
210 Gly Lys Tyr Val Ala Ser Val Lys Val Glu Gly Asn Ala Ser Val Ala
211      85      90      95
213 Ser Ile Thr Ala Thr Met Asn Ser Ser Asn Val Asn Lys Asp Ile Lys
214      100      105      110
216 Gly Lys Thr Leu Val Leu Val Gly Lys Gln Asn Ser Gly Ser Val Lys
217      115      120      125
219 Trp Phe Cys Gly Gln Pro Val Thr Arg Asp Asn Ala Asp Asn Asp Asp
220      130      135      140
222 Val Lys Asp Ala Gly Asn Asn Gly Ile Glu Thr Lys His Leu Pro Ser
223 145      150      155      160
225 Thr Cys Arg Asp Thr Ser Ser Asp Ala Lys
226      165      170
230 <210> SEQ ID NO: 5
231 <211> LENGTH: 30
232 <212> TYPE: DNA
233 <213> ORGANISM: Neisseria gonorrhoeae
235 <400> SEQUENCE: 5
236 cccgcgcgcca tggataccct tcaaaaaggc 30
239 <210> SEQ ID NO: 6
240 <211> LENGTH: 30
241 <212> TYPE: DNA
242 <213> ORGANISM: Neisseria gonorrhoeae
244 <400> SEQUENCE: 6
245 gggcctggat ccgtgggaaa tcacttaccg 30
248 <210> SEQ ID NO: 7
249 <211> LENGTH: 29
250 <212> TYPE: DNA
251 <213> ORGANISM: Neisseria gonorrhoeae
253 <400> SEQUENCE: 7
254 ggctctagac tgtcagacca agtttactc 29
256 <210> SEQ ID NO: 8
257 <211> LENGTH: 27
258 <212> TYPE: DNA
259 <213> ORGANISM: Neisseria gonorrhoeae
261 <400> SEQUENCE: 8
262 ggctctagat tgaagcattt atcaggg 27
264 <210> SEQ ID NO: 9
265 <211> LENGTH: 28
266 <212> TYPE: DNA
267 <213> ORGANISM: Neisseria gonorrhoeae
269 <400> SEQUENCE: 9
270 ggctctagat aaacagtaat acaagggg 28
272 <210> SEQ ID NO: 10
273 <211> LENGTH: 28
274 <212> TYPE: DNA
275 <213> ORGANISM: Neisseria gonorrhoeae

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/674,368A

DATE: 02/06/2002

TIME: 14:15:57

Input Set : A:\33377PCT.APP.txt

Output Set: N:\CRF3\02062002\I674368A.raw

277	<400> SEQUENCE: 10	
278	ggctctagat tagaaaaact catcgagc	28
281	<210> SEQ ID NO: 11	
282	<211> LENGTH: 36	
283	<212> TYPE: DNA	
284	<213> ORGANISM: Neisseria Meningitidis Class I	
287	<400> SEQUENCE: 11	
288	ccccgcgcca tggacaccct tcaaaaaggt tttacc	36
290	<210> SEQ ID NO: 12	
291	<211> LENGTH: 39	
292	<212> TYPE: DNA	
293	<213> ORGANISM: Neisseria Meningitidis Class I	
295	<400> SEQUENCE: 12	
296	gggcctggat ccgagtggcc gtggaaaatc acttaccgc	39
298	<210> SEQ ID NO: 13	
299	<211> LENGTH: 31	
300	<212> TYPE: DNA	
302	<213> ORGANISM: Neisseria Meningitidis Class I	
304	<400> SEQUENCE: 13	
305	ccggcgcgtc tctcacggcg aatggcccgg c	31
307	<210> SEQ ID NO: 14	
308	<211> LENGTH: 39	
309	<212> TYPE: DNA	
310	<213> ORGANISM: Neisseria Meningitidis Class I	
312	<400> SEQUENCE: 14	
313	gggcctggat ccgagtggcc gtggaaaatc acttaccgc	39
316	<210> SEQ ID NO: 15	
317	<211> LENGTH: 25	
318	<212> TYPE: DNA	
319	<213> ORGANISM: Neisseria gonorrhoeae	
321	<400> SEQUENCE: 15	
322	gcataattcg tgctgctcaa ggcgc	25
324	<210> SEQ ID NO: 16	
325	<211> LENGTH: 34	
326	<212> TYPE: DNA	
327	<213> ORGANISM: Neisseria gonorrhoeae	
329	<400> SEQUENCE: 16	
330	gccgcgcgtc tcccgtgatt caggtaatac tcgg	34
332	<210> SEQ ID NO: 17	
333	<211> LENGTH: 25	
334	<212> TYPE: DNA	
335	<213> ORGANISM: Neisseria Meningitidis Class I	
337	<400> SEQUENCE: 17	
338	gcataattcg tgctgctcaa ggcgc	25
343	<210> SEQ ID NO: 18	
344	<211> LENGTH: 39	
345	<212> TYPE: DNA	
346	<213> ORGANISM: Neisseria Meningitidis Class I	
348	<400> SEQUENCE: 18	

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/674,368A

DATE: 02/06/2002

TIME: 14:15:59

Input Set : A:\33377PCT.APP.txt

Output Set: N:\CRF3\02062002\I674368A.raw

13 M:270 C: Current Application Number differs, Replaced Application Number
14 M:271 C: Current Filing Date differs, Replaced Current Filing Date
60 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
64 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
68 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
72 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
76 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
80 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
87 M:258 W: Mandatory Feature missing, <220> FEATURE:
87 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:
194 M:258 W: Mandatory Feature missing, <220> FEATURE:
194 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.